论文部分内容阅读
目的探讨呼吸道合胞病毒肺炎患儿应用清肺口服液的临床实效性,评估分析治疗前后患儿炎症因子水平变化情况。方法 33例呼吸道合胞病毒肺炎患儿,根据治疗方法不同分为观察组(17例)和对照组(16例)。观察组患儿采用清肺口服液治疗,对照组患儿采用利巴韦林注射液治疗,记录比较两组患儿临床治疗总有效率,并通过酶联免疫吸附法(ELISA)测定观察组患儿治疗前后的炎症因子水平[白细胞介素8(IL-8)、细胞间粘附分子1(ICAM-1)]。结果观察组患儿临床治疗总有效率为94.12%,明显高于对照组的62.50%,差异具有统计学意义(P<0.05)。观察组患儿治疗后IL-8、ICAM-1水平均较治疗前明显改善,差异具有统计学意义(P<0.05)。结论采用清肺口服液治疗呼吸道合胞病毒肺炎患儿,临床效果确切,显著改善炎症因子水平,值得在临床领域推广。
Objective To investigate the clinical efficacy of Qingfei Oral Liquid in children with respiratory syncytial virus pneumonia and evaluate the changes of inflammatory cytokines in children before and after treatment. Methods Thirty-three children with respiratory syncytial virus pneumonia were divided into observation group (17 cases) and control group (16 cases) according to different treatment methods. Children in the observation group were treated with Qingfei Oral Liquid, while those in the control group were treated with ribavirin injection. The total effective rate of clinical treatment was recorded and compared between the two groups by enzyme-linked immunosorbent assay (ELISA) Inflammatory cytokine levels before and after treatment [interleukin 8 (IL-8), intercellular adhesion molecule 1 (ICAM-1)]. Results The total effective rate of clinical treatment in observation group was 94.12%, which was significantly higher than that in control group (62.50%), the difference was statistically significant (P <0.05). After treatment, the levels of IL-8 and ICAM-1 in the observation group were significantly improved compared with before treatment, the difference was statistically significant (P <0.05). Conclusion Qingfei oral liquid for the treatment of respiratory syncytial virus pneumonia in children, the exact clinical effect, significantly improve the level of inflammatory cytokines, it is worth promoting in the clinical field.